
Asimov, the Boston-based synthetic biology company focused on mammalian cell engineering, recently launched our industry-leading cell lines for stable viral vector production. Originally developed at MIT, our platform radically advances the design and manufacture of gene therapies and biologics. By integrating state-of-the-art genetic engineering, computational biology, and automation, Asimov enables breakthrough solutions to long-standing challenges in industry. www.asimov.com